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Colorectal cancer is the third most commonly diagnosed cancer, accounting for 53,219 deaths in 2007 and an estimated 146,970
new cases in the USA during 2009. The combination of FDG PET and CT has proven to be of great benefit for the assessment
of colorectal cancer. This is most evident in the detection of occult metastases, particularly intra- or extrahepatic sites of disease,
that would preclude a curative procedure or in the detection of local recurrence. FDG PET is generally not used for the diagnosis
of colorectal cancer although there are circumstances where PET-CT may make the initial diagnosis, particularly with its more
widespread use. In addition, precancerous adenomatous polyps can also be detected incidentally on whole-body images performed
for other indications; sensitivity increases with increasing polyp size. False-negative FDG PET findings have been reported with
mucinous adenocarcinoma, and false-positive findings have been reported due to inflammatory conditions such as diverticulitis,
colitis, and postoperative scarring. Therefore, detailed evaluation of the CT component of a PET/CT exam, including assessment
of the entire colon, is essential.
1. Manuscript
Colorectal cancer (CRC) is a major cause of cancer-related
mortality in Western countries. It is the third most com-
monly diagnosed cancer, with an estimated 146, 970 new
cases diagnosed in the USA during 2009 [1]. In 2007, the
annual mortality rate from colorectal cancer was 20.0 and
14.1 per 100,000 inmen and women, respectively, accounting
for 53,219 deaths [2]. Approximately 80% of patients present
with locoregional disease and 20% with metastatic disease
[3]. Positron emission tomography-computed tomography
(PET-CT) is of considerable assistance to clinicians in the
management of patients with CRC.
2. PET-CT for the Initial Diagnosis of CRC
In practice, FDGPET is rarely used for the primary diagnosis
of CRC although there are circumstances where PET-CT
makes the initial diagnosis (Figure 1).
Precancerous adenomatous polyps can also be detected
incidentally on whole-body images performed for other in-
dications. The sensitivity of PET-CT in this setting improves
with increasing polyp size [4, 5]. CT can help distinguish
benign from malignant causes of abnormal FDG uptake,
and combined PET-CT clearly performs better than either
modality in isolation (Figure 2).
Conventional CT is limited in the detection of subtle
colonic polyps and tumors although contrast-enhanced CT
with oral contrast can be helpful in detecting gross masses
and assessing their complications. CT colonography with a
distended, clean colon is now accepted as a screening test for
CRC with a high accuracy for detecting both adenomatous
polyps and malignant tumors (Figure 3) [6].
The sensitivity of CT colonography for the detection of
CRC is approximately 95% which compares very favorably
with that of barium enema (94%) and optical colonoscopy
(92%) [7]. PET-CT colonography, while being an intriguing
prospect, may have too great a radiation load for a screening
study but may yet prove appropriate for selected indications
[8]. CT colonography and indeed all CT applications
have benefited from the recent dramatic advances in CT
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Figure 1: Rectal carcinoma depicted on PET-CT. (a) There is circumferential rectal thickening (arrow) on contrast-enhanced CT. (b) There
is avid FDG radiotracer uptake (arrow) on axial FDG-PET. (c) Increased FDG uptake on FDG-PET correlates with thickening (arrow) due
to rectal carcinoma seen on CT.
technology with multidetector scanners now up to 320
slice allowing isotropic imaging, increased speed, resolution,
and 3D reconstructions which referring physicians can also
find helpful. CT radiation dose optimization is also now
a more realizable goal with the development of various
dose reduction strategies such as automated iterative recon-
struction techniques and automatic tube current modulation
(Figure 4) [9].
3. PET-CT for the Staging of CRC (T Staging)
Accurate preoperative staging is essential to estimate progno-
sis and institute appropriate therapy in CRC.
Locoregional staging of CRC by imaging can be per-
formed using transrectal ultrasound, magnetic resonance
imaging (MRI), and CT while metastatic disease is best
assessed with CT, MRI, 18-flourine fluorodeoxyglucose
(FDG) PET, and more recently PET-CT. FDG PET is
unsuitable for precise local and regional staging primarily
due to its limited spatial resolution, where precise depth
of invasion is the primary determinant. Therefore, current
staging schemes are based on surgical and pathologic data.
PET may be accurate in selected cases of gross serosal
penetration and local invasion. CT allowsmore precise struc-
tural information than PET, but usually cannot discriminate
bowel wall layers in the manner of MRI or endoscopic US.
Table 1: Sensitivity and specificity of endoscopic ultrasound, CT,
and MRI for perirectal and adjacent organ invasion [10].
Sensitivity (%) Specificity (%)
Perirectal Invasion
Endoscopic Ultrasound 90 75
CT 79 78
MRI 82 76
Adjacent Organ Invasion
Endoscopic Ultrasound 70 97
CT 72 96
MRI 74 96
A meta-analysis from 2004 of endoscopic US, CT, and MRI
for the assessment of perirectal invasion by CRC reported
a significantly higher sensitivity estimate for US than for
CT (P < .001) and MR imaging (P = .003), indicating
understaging of T3 (or higher) tumors with CT and MR
imaging (Table 1). The specificity estimates for US, CT, and
MR imaging as well as the sensitivity and specificity of US,
CT, and MRI for the detection of adjacent organ invasion
were reported as comparable [10].
T staging of CRC by PET-CT is thus almost exclusively
CT dependent. T staging of rectal malignancy has seen many
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Figure 2: Colovesical fistula in a patient with a prior history of anterior resection for rectal carcinoma. (a) There is a connection (arrow)
between the colon and bladder on coronal CT. (b) The colonic end of the fistulous tract (arrow) is seen on axial CT. (c) There is a focus of
avid FDG-PET uptake (arrow) present. (d) Fused images confirm that the uptake is within the fistula (arrow) and probably represents urine
containing FDG within the fistulous tract. The presence of the fistula and the absence of tumor were confirmed at cystoscopy.
advances in recent years. In the setting of rectal cancer,
endorectal ultrasound is very accurate for staging superficial
T1 and T2 tumors but less so for T3 and T4 tumors [11].
The imaging of T3 and T4 tumors is better performed with
either MRI or CT (Figure 5). Recent studies have shown
MRI using a phased array coil to be highly accurate and
the imaging method of choice for staging primary rectal
tumors and assessing for involvement of themesorectal fascia
[12]. Preoperative MRI is not feasible in all patients, and
multislice CT is a potential “one-stop” method of imaging
the mesorectum and identifying distant metastases. The
accuracy of multislice CT for the evaluation of mesorectal
extension by rectal carcinoma is dependent on the site of
the primary tumor. Overall sensitivity and specificity for
predicting mesorectal fascial involvement using CT are 74%
and 94%, respectively. For tumors in the lower third of the
rectum the sensitivity and specificity are reduced at 66%
and 82%, respectively. Sensitivity and specificity of CT for
assessing mesorectal extension are much better for tumors of
the upper two-thirds of the rectum (76% and 96%, resp.),
mainly due to the more generous amount of perirectal fat
enveloped by the mesorectal fascia at higher levels [13].
4. PET-CT for the Staging of CRC (N Staging)
Over 75% of patients with CRC have disease limited to
the bowel or regional pericolic or mesenteric lymph nodes
at diagnosis [14]. Therefore, most surgeries are performed
with curative intent. Regional lymph node involvement
is best determined by surgical-pathologic resection and
analysis. Preoperative nodal staging using imaging requires
an assessment of the number of pericolic and mesenteric
nodes containing metastatic disease. False-negative PET
findings in regional metastatic lymph nodes are in part due to
the intense FDG uptake by the primary site, which obscures
the immediately adjacent structures, and also due to PET’s
low sensitivity for microscopically involved lymph nodes.
For these reasons, FDG PET has been found to be only
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Figure 3: Carcinoma at the rectosigmoid junction at CT colonog-
raphy. There is enhancing tissue at the rectosigmoid junction with
circumferential wall thickening (arrow), shouldered margins, and
luminal stenosis consistent with carcinoma.
29% sensitive for regional lymph nodemetastases fromCRC,
whereas the specificity of FDG PET is 96% [15, 16]. Enlarged
and nonenlarged FDG avid lymph nodes can be identified
in the mesentery on PET-CT, indicating the presence of
regional lymph node metastases, but this is more commonly
encountered on restaging patients with CRC rather than
on initial staging. The presence of only regional lymph
node metastases on PET-CT performed for initial staging
would not in any event preclude resection of the primary
lesion. Similarly, local regional nodes are resected by surgical
excision nonetheless, an attempt to detect nodal or organ
metastases preoperatively using PET-CT is important in
planning the general therapeutic approach (i.e., palliation
versus curative tumor resection). Furthermore, it has been
reported that PET-CT can alter the staging of CRC compared
with conventional imaging in 31% of cases [17]. Altered
staging as a result of PET-CT changes treatment intent in 8%
of cases, mainly due to revised nodal staging (Table 4).
5. PET-CT for the Staging of CRC
(Metastatic Disease)
5.1. Hepatic Metastases. Carcinoma that has spread outside
regional pericolic or mesenteric lymph nodes is considered
metastatic. Sites of metastatic spread include liver, retroperi-
toneal, and iliac lymph nodes, bone, adrenal glands, and
soft tissue. Contrast-enhanced multidetector-row CT is the
primary imaging modality for the detection, localization,
and characterization of focal liver lesions in many hospitals
[18]. The present authors advocate PET-CT be acquired
using an intravenous (IV) contrast-enhanced portal-venous
phase, fully diagnostic quality CT. This method maximizes
contrast resolution for detection of relatively low attenuation
hepatic metastases, which is lacking in the low-dose non-IV
contrast CT (Figure 6).
This is of particular importance in mucinous metastases
which can be poorly FDG avid. Moreover, portal-venous
phase contrast-enhanced CT optimizes vessel and hepatic
Table 2: Sensitivity and specificity of CT, MR, and FDG PET for
detecting hepatic metastases from CRC [25].
Sensitivity (%) Specificity (%)
CT 84 95
MRI 88 93
FDG PET 94 96
FDG PET/CT 97 97
Table 3: Sensitivity and specificity of CT and PET-CT for detection
of recurrent or metastatic CRC [29].
Sensitivity (%) Specificity (%)
CT 67 63
PET-CT 98 75
segment delineation, should the patient be a candidate for
liver resection surgery.
Given the known benefits of such appropriate liver
metastasectomy for patients with CRC and metastases
confined to the liver, PET-CT plays an important role by
detecting additional extrahepatic sites of disease that would
preclude a curative procedure. Several investigators have
examined the incremental value of FDG PET as a supple-
ment to CT and found that FDG PET oﬀers information
beyond that from CT alone and that this information
often aﬀects patient care. FDG PET combined with CT for
preoperative planning in patients with hepatic metastases
identifies additional sites of extrahepatic disease in 11–32%
of patients [19–21]. This frequently changes management
from a localized treatment strategy to a more systemic
approach with chemotherapy.
FDG PET is highly sensitive for the detection of liver
metastases [22–25]. A recent meta-analysis demonstrated
the sensitivities of CT, MR, and FDG PET for detecting
hepatic metastases from CRC to be 83.6%, 88.2%, and
94.1%, respectively, [25] (Table 2). The sensitivity of MR is
improving with the development of newer MR technologies,
andmodernMR is superior to CT for detecting lesions which
measure less than 1 cm [25]. PET is accurate for identifica-
tion of hepatic metastases greater than 1 cm in diameter but
is limited in its ability to demonstrate lesions smaller than
1 cm [26–28]. PET-CT imaging may be particularly useful
in patients with several hypodense or hypoenhancing liver
lesions that are not clearly characterized by CT alone and in
patients in whom standard CT fails to detect metastases in
the setting of a rising serum CEA. In these cases, PET-CT can
direct patient management by guiding biopsies or ablations
or directing surgical resections of liver metastases.
FDG-PET and PET-CT can help clarify abnormal CT
findings and depict otherwise unsuspected metastases to
nonenlarged lymph nodes. PET-CT can often find sites of
disease in patients with abnormal carcinoembryonic antigen
(CEA) levels and prior negative workup with conventional
diagnostic modalities. A recent study of PET-CT for the
detection of recurrent or metastatic disease in patients with
a history of CRC and raised CEA found PET-CT to be
considerably better than multislice CT alone [29] (Table 3).
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Figure 4: Rectal carcinoma with spread to the internal iliac chain lymph nodes. (a) There is an abnormally enhancing iliac lymph node
(arrow) on contrast-enhanced CT. (b) There is avid radiotracer uptake (arrow) on the right side of the pelvis on FDG-PET (arrow). (c)
Increased uptake on FDG-PET (arrow) correlates with the lymph node lesion seen on CT and is consistent with a malignant deposit.
PET-CT for preoperative staging has been shown to improve
survival in patients with hepatic metastases deemed suit-
able for hepatic resection mainly again by demonstrating
the presence of extrahepatic metastases, thus appropriately
eliminating ineﬀective surgery in patients with inoperable
disease [19]. Indeed, FDGPET in patients with CRC is a cost-
eﬀective technique that often changes patient management
[30]. Early identification of liver metastases provides the
opportunity for neoadjuvant chemotherapy and resection,
which again may prolong survival in such patients with CRC
[23, 31].
Liver metastases from CRC represent 50% of all recur-
rences. The size and number of hepatic metastases and
the presence of extrahepatic disease aﬀect the prognosis.
Untreated patients with limited metastases to the liver have
a 5-year survival rate of 28% and long-term survival with
chemotherapy alone is equally dismal [32, 33]. Surgical
resection is the only potentially curative therapy in these
patients. Patients most suited to undergo liver resection
are those with fewer than four lesions, smaller than 5 cm,
and without extrahepatic disease [34]. Recurrence rates after
resection of liver metastases are high however, and there
is significant associated morbidity and mortality. Surgical
treatment oﬀers 5-year survival rates of 25% to 37% and 10-
year survival rates of 20% [35–37].
5.2. Lymph Node Metastases. CRC spread to lymph nodes
beyond regional pericolic or mesenteric lymph nodes is
considered metastatic spread (M1 disease). CT’s strengths
are its accurate depiction of anatomic abnormalities and
its ability to define structures that are below the resolution
of conventional nuclear medicine imaging. A major limi-
tation of CT, however, is its reliance on anatomic criteria
in order to identify pathologic conditions, for example
using a 1 cm short-axis dimension threshold for pathologic
lymphadenopathy. Although this criterion usually results in
an acceptable balance between sensitivity and specificity for
disease, nodes smaller than 1 cm can contain malignant cells
and, in addition, reactive or inflammatory processes can
result in nodes larger than 1 cm. Furthermore the upper
limit of what should be considered normal sized lymph
nodes by CT varies with the specific location but, in general,
is accepted to be 10mm in short axis for retroperitoneal,
mesenteric, external iliac, and inguinal nodes, 8mm for
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Figure 5: Large upper rectal adenocarcinomawith possible involve-
ment of the bladder wall there is a large aneurysm-type carcinoma
(arrow) of the rectum present with stranding of the fat between the
tumor and the bladder which is concerning for bladder involvement
which would classify the tumor as T4.
internal iliac, obturator, and lateral sacral nodes and 5mm
for perirectal nodes. Other overlapping CT nodal features
that can be seen with lymph node metastases and inflam-
matory conditions include low density (as in mucinous
metastases) and calcifications.
Nodal metabolic activity assessment using FDG PET is
not directly reliant on nodal size to determine the presence
or absence of malignancy. Nodes that are not enlarged can
contain tumor on FDG PET images, and nodes that are
enlarged can be shown to be reactive in nature. For this
reason, PET is more sensitive and specific than CT alone
for identification of lymph node metastases [38]. However,
PET also has limitations regarding size, as false-negatives can
occur in small lymph nodes and false-positives may occur
due to inflammation. In addition some cystic or mucinous
nodal metastases may not show significant FDG uptake, and
hence the FDG PET images cannot be entirely relied upon to
exclude lymph node metastases in the setting of CRC.
5.3. Pulmonary Metastases. The lung is the second most
common organ for colorectal metastatic diseases. Pulmonary
metastatic disease manifests as pulmonary nodules, lym-
phangitic carcinomatosis, and thickening of the pulmonary
interstitium or of the pleura. Ten percent of patients with
CRC develop lung metastases, usually in association with
other extrathoracic systemic disease. But 2–4% will have
isolated lung metastases and 50% of these will be amenable
to resection [39, 40]. The sensitivity and specificity of
PET-CT for the detection of malignant solitary pulmonary
nodules are 96% and 83%, respectively, [41]. Peroperative
morbidity is low, and 5-year survival ranges from 28% to
40% after successful resection [39, 40, 42, 43]. The CT
component of PET-CT provides high resolution and is thus
the first choice for lung nodule detection, and the FDG PET
component improves specificity for nodules generally greater
than 8mm. Standard chest CT is now able to delineate
pulmonary nodules as small as 2-3mm. This facilitates the
detection of even the smallest pulmonary nodules, leading
to a therapeutic dilemma because the low specificity of such
findings (most pulmonary nodules will be benign) remains a
problem [44] (Figure 7).
Furthermore, in daily practice, atypical imaging features
of metastases are often encountered making a distinction of
metastases from other benign pulmonary diseases based on
CT findings alone diﬃcult. Due to limited spatial resolution,
a negative PET scan cannot exclude pulmonary metastases
with certainty, while a positive FDG-PET will generally
confirm suspicious abnormalities detected on the CT images
[45]. A standardized uptake value (SUV) of greater than 2.5
suggests that a solitary pulmonary nodule is malignant with
a relatively high degree of sensitivity and specificity [46].
Known nonmalignant causes of increased FDG uptake in
the lung parenchyma include inflammatory processes such as
granulomatous disease, cryptogenic organizing pneumonia,
tuberculosis, and aspergilloma, while previous talc pleu-
rodesis can result in false-positive uptake in the pleura
[47]. Respiratory gating during the acquisition of PET-CT
shows potential for better spatial resolution on FDG-PET
and improved correlation between nodule SUV values and
nodule size [48].
5.4. Osseous Metastases. Osseous metastases from CRC are
relatively uncommon. A review of over 5,000 cases reported
osseous metastases combined with visceral metastases in
6.6% and isolated skeletal metastases in 1.1% of cases [49].
Osseous metastases may be overlooked on CT particularly
if metastatic disease is confined to the skeleton or if the
patient has coexistent osteoporosis. Typical appearances of
bone metastases on CT include lytic or mixed lytic/sclerotic
lesions which can become sclerotic with treatment. FDG
uptake in bone marrow is usually roughly equivalent to,
or slightly greater than, that of liver background tracer
activity. FDG uptake in marrow of the vertebral bodies can
appear focal on axial imaging and can be misinterpreted.
A repeating regular pattern usually best appreciated on
sagittal or coronal images is characteristic of physiologic
marrow FDG uptake. Metastases are distinguished by more
intense FDG uptake and a nonuniform distribution. Patients
undergoing treatment with hematopoietic stimulates as part
of their chemotherapy regimen can demonstrate uniformly
high marrow FDG accumulation, and thus PET imaging
ideally should not be scheduled immediately after their
administration [50].
Studies suggest that PET-CT is both sensitive and specific
for diagnosing malignant bone lesions [51]. For example,
one study of 712 patients, 59 of whom had bone metastases,
demonstrated PET/CT to have a positive predictive value of
98% when findings on PET and CT were concordant [52].
Focal FDG uptake on PET often draws attention to subtle
bony changes of early metastases on the CT. Occasionally
no corresponding CT abnormality is seen and if deemed
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Figure 6: Liver metastatic deposit in a fatty liver that is diﬃcult to appreciate on CT. (a) There is diﬀuse fatty infiltration of the liver on
unenhanced CT with attenuation values in the liver far lower than those of the spleen. (b) There is a very subtle lesion (arrow) in segment 7
on contrast-enhanced CT imaging. (c) There is avid radiotracer uptake (arrow) in the right lobe of liver FDG-PET. (d) Increased uptake on
FDG-PET (arrow) correlates with the subtle liver lesion on fused PET-CT consistent with a hepatic metastasis.
necessary MRI may be helpful to clarify discordant PET-CT
findings. Increased osseous FDG uptake can occur secondary
to fractures, hemangiomata, or increased hematopoietic
activity in patients receiving chemotherapy [53].
5.5. Other Soft Tissue Metastases. Peritoneal implants due
to colon cancer can be diﬃcult to detect on CT alone
particularly in cachectic patients without careful attention
to technique and interpretation. FDG PET images are very
useful for locating peritoneal implants 7-8mm or greater in
size. The adrenal glands are another favored site for colorectal
metastases for which PET imaging is very sensitive. Adrenal
adenomas can uncommonly exhibit increased FDG activity,
and all of the reported cases of PET-positive adenomas have
been indeterminate by CT criteria (>10HU). Analysis using
CT contrast washout analysis may be useful for further lesion
characterization but adrenal biopsy is the final arbiter for
metastases if histologic confirmation is required.
6. Restaging of CRC
Locoregional pelvic recurrence and liver metastases are the
major sites of relapse after resection of CRC. Recurrence
occurs in one third of patients in the first 2 years after
resection. Patterns of recurrence are diﬀerent in colon cancer
compared with rectal cancer. Local recurrence is more
common in patients with rectal rather than colon cancer
ranging from 7% to 33% and 1–19%, respectively, [54].
Only 20% of local recurrences can be completely resected,
and most patients who develop local recurrence die from
their disease [55]. Several studies have reported on the
spread and survival patterns regarding local, locoregional,
and metastatic recurrence. Willett et al. reviewed recurrent
colon carcinoma, finding that 20% of recurrences were local
failures only and 43%were concurrent local and distant [56].
Pilipshen et al. found that 30% of the recurrences were pelvic
alone and 58% were both pelvic and distant [57]. Tumor
stage, perforation, local invasion, and rectal carcinoma
are positive predictors of recurrence [58]. Brethauer et al.
reported that 54% of recurrences had distant metastases
alone at the time of recurrence and 67% had distant
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Figure 7: Patient with rectal carcinoma and mildly FDG avid metastases to lung. (a) There is a suspicious right upper lobe lung nodule
(arrow) on CT in a patient with prior history of rectal carcinoma. (b) The lesion is only mildly FDG avid (arrow) on fused PET-CT. Based
on these images the lesion is not definitively malignant. This may be due to the limited resolution of PET and the small lesion size or reduced
cellularity. (c) Lung biopsy was subsequently performed confirming that the lesion (arrow) represented a metastatic deposit from rectal
carcinoma.
metastases as a component of failure [55].
Focal FDG uptake guides radiologists to examine the
corresponding CT for concordant abnormalities such as a
soft tissue mass or bone erosion on CT. Correlation with a
patient’s clinical status is also vital in PET-CT interpretation
as some imaging features overlap between abscess and cystic
metastatic disease. Mucinous adenocarcinoma of the colon
can cause widespread intraperitoneal metastases, which can
be detected with CT only if they produce thickening of
the peritoneal surfaces or peritoneal nodules. Microscopic
seeding of the peritoneal surfaces will not be detected by
either CT or PET. However, the combination of CT and PET
together can help identify macroscopic peritoneal implants.
Diﬀerentiating the posttherapy appearances such as
surgical scarring and radiation fibrosis from disease recur-
rence is particularly challenging in patients with CRC. This
problem is mostly encountered with distal colon and rectal
tumors, where presacral scarring and pelvic changes are
common. Serial examinations are frequently required using
conventional imaging, before slowly developing changes can
be appreciated over time. Metabolic activity in the presacral
space is indicative of tumor recurrence on FDG PET per-
formed 6 months following surgery, while postsurgical
change is not hypermetabolic (Figure 8).
FDG PET is accurate for diﬀerentiation of benign from
malignant presacral changes and is superior to CT and
MR imaging in this regard [59]. Metabolic imaging has a
further advantage in that only a single study is necessary to
make this determination, rather than the serial morphologic
studies often required with conventional imaging. However,
PET alone has limitations given the anatomical changes in
appearance and position seen resulting from surgery. Even-
Sapir et al. documented the additional value of PET-CT in
the detection of pelvic recurrence 6 months or longer after
surgical removal of rectal cancer [60]. PET-CT imaging has
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Figure 8: Local recurrence 2 years following resection of rectal carcinoma. (a) There is soft tissue material in the presacral space (arrow)
that may be postoperative in nature but the presence of malignancy is diﬃcult to exclude on CT alone. (b) There is a small focus of avid
radiotracer uptake (arrow) on the on FDG-PET. (c) Increased uptake on FDG-PET (arrow) correlates with the presacral soft tissue (arrow)
and is characteristic of tumor recurrence in a patient who has not had recent surgery in this area and has no symptoms of leak or infection.
the potential to become the preferred imaging modality in
these patients, because it identifies and localizes the disease
in one setting and can guide diagnostic or therapeutic
interventions [61]. Surgical management of local recurrence
depends on the site and extent of the disease. PET-CT can
be particularly useful for demonstrating recurrent rectal
cancer involving adjacent pelvic organs, pelvic sidewalls, or
sacrum and for planning potential pelvic exenteration, en
bloc resection, or palliative diversion procedures.
Wound recurrences are rare and, although resectable
when isolated, are usually indicative of diﬀuse intraabdom-
inal disease. Isolated recurrence can occur at the site of
prior resection of metastases and PET-CT can be helpful
in precisely locating and characterizing such recurrences.
Similarly, anastomotic recurrences may be resected but can
be associated with more extensive local or metastatic disease,
demonstrable by PET/CT, which would usually preclude
resection.
7. Reporting of PET-CT in CRC
Dictating a concise and pertinent PET-CT report of a study
performed on a patient with CRC firstly requires an accurate
clinical history be available so that individual specific ques-
tions can be addressed. Relevant issues include the patient’s
preoperative or postoperative status, prior imaging, and
colonoscopic findings. The oncologist often wants to know
of findings pertinent to staging or restaging and the develop-
ment of complications from the tumor or issues requiring
intervention such as abscess, venous thrombosis, bowel
obstruction, perforation or urinary tract obstruction. The
surgeon may seek specific factors that will influence potential
operations including vascular relationships or postoperative
complications. Relevant nonneoplastic findings should also
be recorded. Pertinent negatives and positives should be
detailed in the body of the report, and specific issues,
conclusions, and recommendations stated in the impression.
Important or unexpected findings should be directly com-
municated to the referring physician.
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Table 4: Sensitivity and specificity of FDG PET and PET-CT for detecting pelvic recurrence of CRC [60].
Sensitivity (%) Specificity (%) Accuracy (%)
FDG PET 82 65 93
PET-CT 98 96 74
In patients without a known history of CRC, it is
important to be aware that colonic FDG uptake may be
quite avid in the absence of pathology particularly in the
cecum/ascending colon and within the rectoanal region.
Moreover, inflammatory conditions such as Crohn’s disease,
ulcerative colitis, typhlitis, and diverticulitis can all lead
to increased colonic FDG activity. Regardless of etiology,
however, focal large bowel activity greater than hepatic
activity is unusual and should alert the interpreting physician
to the possible presence of pathology. A thorough regional
review of coregistered CT images is warranted to assess for
focal masses or neighboring signs of inflammation bearing in
mind that peristalsis, patient motion, and breathing may lead
tomisregistration of the PET and CT images. A long segment
of diﬀusely increased colonic FDG uptake should not be
interpreted as inflammatory bowel disease unless there are
coexistent CT findings as this pattern of uptake is not
uncommonly seen. In the absence of specific corresponding
benign CT findings, focal intense colonic activity on PET
usually warrants further investigation such as colonoscopy.
8. False-Negative FDG-PET Findings
As mentioned earlier, false-negative FDG PET findings have
been reported with mucinous adenocarcinoma since the
sensitivity of FDG-PET for mucinous adenocarcinoma is
significantly lower than that for nonmucinous disease [62].
Detailed diagnostic evaluation of the entire CT component
including the entire colon is therefore an essential part of
PET/CT interpretation. Readers of PET-CT need also to
be cognizant of the impact of diﬀerent degrees of rectal
and bladder distention can have particularly on pelvic
disease coregistration. Similarly caution must be exercised
when interpreting liver metastases, as dome lesions can be
erroneously projected onto the lung base due to respiratory
artifact. False-negative results on FDG PET are particularly
common within 4 weeks of chemotherapy. This is thought
to be due to chemotherapy, induced cessation of metabolic
activity resulting in apoptosis and cell death. A recent study
of 224 patients with colorectal hepatic metastases demon-
strated that FDG PET within 4 weeks of chemotherapy had
a negative predictive value of 13% and a positive predictive
value of 94% [63].
Fistulous tracts, sinus tracts, and abscesses will typically
be associated with intense abnormal FDG tracer uptake,
and careful review of the CT images is important in the
setting of abnormalities in the region of anastomoses of
colon or rectum, and in general in the presacral region in the
setting of treated rectal cancer. When a fistula is suspected or
questioned, oral contrast becomes particularly important to
diﬀerentiate neoplasm from physiologic inflammatory tracer
uptake.
9. TherapyMonitoring with PET-CT
PET-CT is likely the optimal method for detecting recurrence
and monitoring treatment response to chemotherapy and
radiotherapy in CRC although, in practice, CT is still
most commonly used for this purpose [64, 65]. Complete
resolution of abnormal glucose metabolism in primary and
metastatic lesions of colon cancer can be observed following
chemotherapy. FDG-PET can be used to predict response to
chemotherapy and radiofrequency ablation in patients with
hepatic metastases from CRC [66, 67]. However, many issues
including optimal time for imaging, criteria for response,
and the decision-making and cost-eﬀective benefits of PET-
CT imaging for monitoring therapy response in patients with
CRC have not yet been fully established.
10. Planning of Radiation Therapy for CRC
Using PET-CT
Radiation combined with surgery and chemotherapy is
employed for patients with stage II and III rectal cancer.
Radiation is associated with a reduced rate of local recurrence
but also increases the risks of sexual dysfunction, postop-
erative mortality in older patients, and perineal dehiscence
[68]. Cross-sectional imaging such as CT and MR imaging
is the most common method for planning radiation therapy
in patients with CRC. These structural imaging techniques
provide anatomic delineation of tumor mass and adjacent
structures as well as an estimation of tumor volume in
three dimensions. However, these techniques have certain
challenges including, firstly to diﬀerentiate a primary or
recurrent malignant lesion from surrounding inflammatory
changes or fibrosis, secondly to correctly represent time-
averaged position and shape of the tumor due to patient
motion, and finally to accurately take into account the
metabolic and biologic features of cancer.
PET-CT imaging for radiation therapy planning has been
found to be useful in patients with brain, lung, head, and
neck, as well as pelvic cancers (including CRC) [69]. The
eﬀect of PET data from an integrated PET-CT system, in
addition to the CT images for defining the gross tumor
volume (GTV) and as a consequence the clinical tumor
volume (CTV) and planning target volume (PTV), has been
investigated [69]. GTV increases were observed in three
of 6 patients. The mean changes of the GTV were 50%,
translating into a 20% change of PTV. PET has the potential
to improve the rate of negative margins after surgery, and
PET-CT-based radiotherapy planning may help minimize
portal field sizes without missing macroscopic tumor tissue
adjacent to the primary tumor. PET-defined GTV is also
potentially useful for planning the boost volume for adjuvant
radiation therapy after tumor resection of rectal cancer if
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Table 5: Advantages and disadvantages/pitfalls of combined PET-CT.
Advantages Disadvantages/potential pitfalls
Physiological information with poor spatial resolution of
FDG-PET combined with the high spatial resolution of CT
yields a study that is better than either component on their
own
Potential for false-positive results in the postoperative bed within 4
weeks of surgery
Improved sensitivity and specificity for staging colorectal
cancer, detecting local recurrence and metastases
High radiation dose
Potential false-negative results with variations in rectal distension and
mucinous adenocarcinomas which often do not take up FDG and in
lymph nodes measuring less than 1 cm in size
Can be used to predict response to chemoradiotherapy and
plan radiotherapy
Potential false-positive results due to the presence of abscesses, sinus,
or fistulous tracts
PET-CT is obtained in the radiotherapy position before
surgery. PET-CT imaging can be useful for planning laser-
induced thermotherapy for liver metastases from CRC [70].
Metastases with increased FDG uptake, which are diﬃcult
to localize on PET images alone, can be better identified
with fused PET-CT image data. Detection of lesions not
seen on CT images can facilitate in planning of laser-
induced thermotherapy (and other local treatments) for
liver metastases as well as in the identification of patients
with extrahepatic metastases, who may not profit from the
procedure.
FDG PET and PET-CT can provide added diagnos-
tic information compared with conventional imaging in
patients after radiofrequency ablation of liver metastases
and can be used to guide repeat ablations [71]. Areas of
focal FDG accumulation greater than background activity
in the region of the treated lesion are interpreted as being
pathologic. OnCT an irregular, hypoattenuating area around
the margins of the ablated tumor that increases in size on
followup scans is interpreted as residual tumor. In one of
study 4 of 17 patients whose unresectable liver metastases
were treated by RFA, FDG-PET at 1 week and 1 month
showed peripheral focal hypermetabolic residue after RFA,
whereas CT did not reveal the residual tumor [72]. FDG-
PET appears to accurately monitor the local eﬃcacy of RFA
for treatment of liver metastases, as it recognizes incomplete
tumor ablation earlier than detectable on CT. Langenhoﬀ et
al. reported similar findings but we consider comparison of
the PET findings with CT essential and should preferably
be performed as part of a PET-CT examination [73]. These
studies support the use of FDG PET in combination with CT
scan in the follow-up of RF ablated colorectal metastases and
PET-CT may lead to earlier detection of tumor recurrence
than conventional imaging modalities.
11. Conclusion
The development of PET-CT has had a considerable impact
on the assessment of patients with CRC and it helps
decide if treatment intent should be curative or palliative
(Table 5). The impact of PET-CT is the greatest for the
detection of previously unrecognized sites of metastatic
disease, either hepatic or extrahepatic, patients with a rising
CEA, and for the detection of local recurrence. A single PET-
CT can diagnose local recurrence due to abnormal FDG
uptake, whereas serial conventional CTs are often required
to characterize recurrence. Similarly, PET-CT does not rely
solely on anatomic size to diagnose nodal metastases as is the
case with conventional CT. The spatial resolution of PET-CT
is approximately 1 cm, and limited FDG uptake by certain
tumor cell types such as mucinous adenocarcinoma repre-
sents another potential weakness. Increased FDG uptake can
occur due to benign disease such as diverticulitis, fistulas, and
sarcoid. Future directions for the development of PET-CT
will be determined by methods of radiation dose reduction,
increasing resolution, newer more specific isotopes, and
the continued close working relationship between referring
physicians and radiologists.
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